Doseology Sciences Inc. announced the appointment of Shawn Balaghi the Interim CEO and Interim CFO of the company, effective immediately. Shawn brings over 20 years of experience in the capital markets industry globally, holding key roles in finance, corporate development, and strategic planning. Previously, he has served as the CEO and CFO, and Director for several publicly listed companies and has worked closely with some of the largest independent auditing firms in Canada and the US.

Shawn has raised over $300 Million in funding for several start-ups and has led them to public listings in Canada, the US, and Germany. Shawn has been the President, Director &Co-Founder of RED Bioscience since July 2020, and successfully ran trials at the University of British Columbia on an all-natural formulation preventing and deactivating several variations of the Covid Virus. The company also announced that Pratik Patel has resigned as the CFO, Interim CEO and director of the Company and wishes him well in his future endeavours.